GlassScriptPhysician profile
Gary R Bergman
NPI 1356448971
$2,244.85
in general payments reported to CMS, 2019-2025
26 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $276 · 2021: $241 · 2022: $303 · 2023: $395 · 2024: $343 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.51 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $514.78 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $283.37 | 2019-2024 | Lo Loestrin Fe |
| Organon LLC | $250.21 | 2021-2025 | Nexplanon, Jada System |
| Pfizer INC. | $191.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $130.13 | 2019-2021 | |
| Hologic Sales and Service, LLC | $115.13 | 2019-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $88.33 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $87.38 | 2021-2025 | |
| Therapeuticsmd, INC. | $79.42 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.59 | 2019-2023 | |
| Sage Therapeutics, LLC | $63.52 | 2022-2025 | Zurzuvae |
| Shield Therapeutics INC | $37.40 | 2024 | |
| Urovant Sciences INC | $37.37 | 2022 | |
| Mylan Pharmaceuticals INC. | $34.36 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $32.96 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $30.59 | 2021 | |
| Amgen INC. | $30.32 | 2021 | |
| Smith+Nephew, INC. | $26.85 | 2025 | Pico |
| Daiichi Sankyo INC. | $26.35 | 2024 | Injectafer |
| Sumitomo Pharma America, INC. | $19.38 | 2023 | Gemtesa |
| Kedrion Biopharma, INC. | $18.82 | 2023 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Exact Sciences Corporation | $18.40 | 2025 | The Cologuard Plus Collection Kit |
| Cosette Pharmaceuticals INC. | $15.87 | 2024 | Vyleesi |
| Allergan, INC. | $14.34 | 2019 | |
| Avion Pharmaceuticals | $13.20 | 2021 | |
| Coopersurgical, INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.